Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Danazol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Danazol. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-004400-19 Sponsor Protocol Number: 1707-FIVI-084-MV Start Date*: 2019-05-30
    Sponsor Name:IVIRMA MADRID
    Full Title: Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study.
    Medical condition: low ovarian reserve
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000988-32 Sponsor Protocol Number: VML-0501-001 Start Date*: 2017-10-25
    Sponsor Name:VIRAMAL LIMITED
    Full Title: A Comparative, Open-Label, Randomized, Parallel Group Study to determine Intraperitoneal fluids, tissue, and serum concentrations of VML-0501 following five days of daily vaginal applications of si...
    Medical condition: endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10014789 Endometriosis, site unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000583-18 Sponsor Protocol Number: SRA-MMB-301 Start Date*: 2020-01-07
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera...
    Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028538 Myelofibrosis with myelometaplasia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) DK (Completed) FR (Ongoing) CZ (Completed) ES (Restarted) PL (Completed) HU (Completed) AT (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-003642-15 Sponsor Protocol Number: Belimumab bei ITP Start Date*: 2008-06-05
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects
    Medical condition: Autoimmune thrombocytopenia (ITP) is a common disorder in which platelets are destroyed by autoantibodies. BAFF has been shown to be elevated in the serum of ITP patients. Blockage of BAFF has be...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001686-17 Sponsor Protocol Number: P170925J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition: Patients older than 15 years with hematologic or pulmonary lesions of telomeropathies.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062759 Congenital dyskeratosis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000367-98 Sponsor Protocol Number: TRA100773 Start Date*: 2005-02-11
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin recep...
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) EE (Completed) LV (Completed) IE (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017942-30 Sponsor Protocol Number: 0914M0622 Start Date*: 2010-06-15
    Sponsor Name:Shionogi USA, Inc.
    Full Title: An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy
    Medical condition: Relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066667 Chronic thrombocytopenia LLT
    12.1 10063129 Persisting thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016950-42 Sponsor Protocol Number: 0913M0621 Start Date*: 2010-06-15
    Sponsor Name:Shionogi USA, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of S-888711 tablets administered once-daily for 42 days to adult subjects wi...
    Medical condition: Relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066667 Chronic thrombocytopenia LLT
    12.1 10063129 Persisting thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) HU (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000470-78 Sponsor Protocol Number: TRA102537 Start Date*: 2006-10-30
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004774-97 Sponsor Protocol Number: C-935788-057 Start Date*: 2019-10-23
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed) ES (Completed) CZ (Completed) HU (Completed) DK (Completed) DE (Completed) AT (Completed) BE (Completed) NL (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001671-21 Sponsor Protocol Number: KRT-232-101 Start Date*: 2018-10-03
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed P...
    Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) HU (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing) LT (Ongoing) IT (Ongoing) PT (Ongoing) HR (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004162-18 Sponsor Protocol Number: PDY16894 Start Date*: 2021-03-16
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A multicenter, Phase 2a, open-label, non-randomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune thrombocytopenia (ITP)
    Medical condition: immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004055-37 Sponsor Protocol Number: ALXN1830-WAI-201 Start Date*: 2020-05-06
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia
    Medical condition: WAIHA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000557-27 Sponsor Protocol Number: M20-178 Start Date*: 2020-09-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis...
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) BE (Completed) SE (Ongoing) PL (Ongoing) GR (Ongoing) AT (Ongoing) DK (Ongoing) IT (Ongoing) BG (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002943-10 Sponsor Protocol Number: TRA108057 Start Date*: 2007-04-19
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: REPEAT. Repeated ExPosure To Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura. An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chron...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000471-14 Sponsor Protocol Number: TRA105325 Start Date*: 2006-06-13
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopa...
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SE (Completed) DE (Completed) ES (Completed) IE (Completed) NL (Completed) GR (Completed) FR (Completed) SK (Completed) GB (Completed) CZ (Completed) DK (Completed) IT (Completed) FI (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005452-15 Sponsor Protocol Number: C-935788-047 Start Date*: 2014-09-11
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
    Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10067644 Immune-mediated thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-005453-76 Sponsor Protocol Number: C-935788-048 Start Date*: 2014-09-11
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
    Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10067644 Immune-mediated thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-004103-12 Sponsor Protocol Number: TAK-079-1004 Start Date*: 2021-02-22
    Sponsor Name:Takeda Development Center Americas, Inc. (Takeda)
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SI (Ongoing) BG (Ongoing) HR (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002100-41 Sponsor Protocol Number: ARGX-113-1801 Start Date*: 2019-11-01
    Sponsor Name:argenx BVBA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immun...
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) HU (Completed) CZ (Completed) ES (Completed) PL (Completed) BE (Completed) DE (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA